BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » news » Page 4

Could Google Be the Next Big Force in Regenerative Medicine?

February 10, 2017 By Cade Hildreth (CEO) 1 Comment

Google Regenerative Medicine

Google has been massively (and quietly) increasing its presence in the regenerative medicine sector for several years.

Verily, Google Life Science BusinessIn February 2016, Google’s life sciences business, Verily Life Sciences, announced it was negotiating terms to lease a giant 400,000-square-foot facility formerly occupied by Onyx Pharmaceuticals, a company acquired by Amgen for $9.7 billon in 2013.

The facility in Mountain View, California, is about 30 miles north of Alphabet Inc., the holding company for Google (NASDAQ: GOOG). It could support as many as 1,000 Verily Life Sciences employees. Land is also included in lease, a rarity in the Bay Area, allowing Verily the potential for future expansion.  [Read more…]

Filed Under: Stem Cell News, Stem Cells Tagged With: Google, healthcare, news, regenerative medicine

What is the Most Predictive Cardiac Cell Model? FDA Publication Confirms COR.4U By Axiogenesis

November 11, 2016 By Cade Hildreth (CEO) Leave a Comment

Predictive Cardiac Cell Model - Axiogenesis COR.4U

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs).

There was a publication earlier this year by Astra Zeneca researchers that resulted in a somewhat negative perception (mostly by iPS cell skeptics) of iPSC-derived cells. The predictive value of iPSCs was questioned, with the abstract stating, “iCell® cardiomyocytes have limited value as an integrated QT/TdP assay, highlighting the urgent need for improved experimental alternatives that may offer an accurate integrated cardiomyocyte safety model for supporting the development of new drugs without QT/TdP effects.” [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: Axiogenesis, cardiomyocytes, COR.4U, drug development, news

RIKEN Resuming World’s First Ever Clinical Study of iPSC-Derived Cells in Humans

June 22, 2016 By Cade Hildreth (CEO) 2 Comments

RIKEN Resuming First Ever Clinical Study of iPSC-Derived Cells in Humans

In major news released today, RIKEN announced that it is resuming its retinal induced pluripotent stem cell (iPSC) study in partnership with Kyoto University.

2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB) in Kobe, Japan. Dr. Takahashi and her team were investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. [Read more…]

Filed Under: iPS Cells Tagged With: clinical trial, iPSC, Kyoto University, news, RIKEN

Will Universal Cell’s Gene-Editing Tech Create Universally Compatible Stem Cells?

March 10, 2016 By Cade Hildreth (CEO) Leave a Comment

Universal Cells Interview

Universal CellsUniversal Cells Inc. is a private biotechnology company based in Seattle, Washington that is enabling the field of regenerative medicine by creating stem cells that are universally compatible. Its technology is based on intellectual property (IP) in-licensed from the University of Washington and includes methods for genome editing in human stem cells via homologous recombination with recombinant adeno-associated virus (rAAV) vectors, as well as specific HLA-engineering strategies.

I had the honor to interview Gregory Block, VP of Business Development for Universal Cells. Universal Cells is a private biotechnology company based in Seattle, Washington, that is revolutionizing the stem cell field by creating stem cells that are universally compatible.

[*Note: Universal Cells was acquired by Japanese biopharmaceutical giant Astellas Pharma on February 14, 2018, for $102.5 million plus potential milestones.]
[Read more…]

Filed Under: Interviews, Stem Cells Tagged With: biotechnology, Gregory Block, news, stem cells, Universal Cells

Tisch MSRCNY to Launch Phase II Stem Cell Trial for Multiple Sclerosis (MS)

January 15, 2016 By Cade Hildreth (CEO) 1 Comment

Dr. Sadiq is Leading the Trial Investigating Stem Cells for MS
Tisch MS Research Center of New York
Laboratory for the Tisch MS Research Center of New York

Dedicated to identifying the cause of multiple sclerosis (MS), the Tisch MS Research Center of New York was formally launched in 2006. However, it grew out of the MS center at the Neurological Institute of New York of the Columbia University Medical Center, a group which Dr. Saud Sadiq joined in 1992. [Read more…]

Filed Under: Neural Stem Cells, Stem Cells Tagged With: cell therapy, fda, MS, multiple sclerosis, news, Tisch MSRCNY

  • « Previous Page
  • 1
  • 2
  • 3
  • 4

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.